Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
GRASP logo

We are celebrating a fantastic end to the month and seeing January out with a bang after a bumper recruitment day on 31st January. We recruited 33 patients in January (including an amazing 7 patients on 31st January alone), which smashed our previous record of 25 and enabled us to beat our monthly recruitment target. Thanks and congratulations to all of the sites involved in our record-breaking month – with more sites opening to recruitment we hope to beat this in February!

We are currently open to recruitment in 15 sites, with a further 5 to come on board in the coming months. GRASP is recruiting adults with a new episode of shoulder pain attributable to a rotator cuff disorder.

 

Similar stories

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.